Segall Bryant & Hamill LLC Sells 44,987 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Segall Bryant & Hamill LLC lessened its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 12.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,352 shares of the biotechnology company’s stock after selling 44,987 shares during the period. Segall Bryant & Hamill LLC’s holdings in ADMA Biologics were worth $5,254,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter valued at approximately $31,000. National Bank of Canada FI acquired a new stake in ADMA Biologics in the 3rd quarter valued at $35,000. GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares in the last quarter. Vision Financial Markets LLC acquired a new position in shares of ADMA Biologics during the 4th quarter worth about $51,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of ADMA Biologics in the 3rd quarter valued at about $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Performance

Shares of ADMA opened at $20.28 on Friday. The company has a market cap of $4.79 billion, a PE ratio of 72.43 and a beta of 0.60. The firm has a 50-day moving average of $17.05 and a 200-day moving average of $18.13. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.